Barclays’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Barclays’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-6,600	Closed	-$458K	–	7431
2018 Q3	$458K	Buy	+6,600	New	+$500K	﹤0.01%	4343
2016 Q3	–	Sell	-124,400	Closed	-$4.83M	–	6842
2016 Q2	$4.83M	Buy	+124,400	New	+$5.18M	0.01%	1339

Other funds holding EGRX

SLG

Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return

AIC

Archer Investment Corporation Carmel, Indiana $469M AUM 19.1% 1-Year Est. Return

Barclays's EGRX Position: Q1 2025 in Review

Barclays sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2025, closing a stake of 14,233 shares — an estimated $7.12K sold.

Barclays first reported a position in EGRX in Q1 2014 and held it in 43 quarters. The position peaked at $4.53M in Q3 2016. 2 funds tracked by Wall St. Rank hold EGRX as of Q1 2025.

Barclays reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2025 after selling out during the quarter.
Barclays sold 14,233 Eagle Pharmaceuticals, Inc. shares in Q1 2025, an estimated $7.12K.
Barclays first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2014 and held it in 43 quarters.
Barclays's Eagle Pharmaceuticals, Inc. position peaked at $4.53M in Q3 2016.
2 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2025.

Based on Barclays's 13F filing for Q1 2025, filed 15 May 2025.